Recently released phase 2b clinical trial data shows that an investigational drug product, BDI-001, showed a statistically significant improvement in the signs and symptoms of tinea pedis. The data follows the earlier phase 2a data showing similarly positive results.
In the phase 2b trial, patients applied the product to their own feet once daily for 28 days. Trial analysis showed that DBI-001 reduced the abundance of Trichophyton rubrum, supporting current evidence that tinea pedis is a dysbiosis of the skin microbiome.
In addition to a reduction in T rubrum, the product showed a statistically significant improvement in the signs and symptoms of infection and investigator static global assessment. No safety or tolerability issues were found.
The product currently is being studied in a phase 2 trial as a treatment for onychomycosis as well.
Reference
DermBiont announces positive results from phase 2b clinical trial in tinea pedis. News release. DermBiont; January 8, 2021. Accessed January 8, 2021. https://www.dermbiont.com/in-the-news/2021/1/8/dermbiont-announces-positive-results-from-phase-2b-clinical-trial-in-tinea-pedis
